跳至主要内容
临床试验/ACTRN12617000557336
ACTRN12617000557336终止1 期

A Phase 1a/1b, Blinded, Randomized, Placebo-Controlled Study Evaluating the Safety, Anti-Viral Activity, and Pharmacokinetics of ARB-1740 in Non Cirrhotic, HBV-DNA Negative and Positive Subjects with Chronic HBV Infection.

Arbutus Biopharma Corporation0 个研究点目标入组 30 人开始时间: 2017年4月21日最近更新:
适应症

试验速览

阶段
1 期
状态
终止
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 65 Years(—)
性别
All

入选标准

  • 未提供

排除标准

  • 未提供

研究者

相似试验

尚未招募
1 期
A study to evaluate the safety, tolerability, pharmacokinetics and antiviral activity of BJT-678 in Healthy volunteersChronic Hepatitis D InfectionChronic Hepatitis B InfectionInfection - Other infectious diseases
ACTRN12624001003561Bluejay Therapeutics, Inc.80
进行中(未招募)
1 期
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b when added to standard of care anticoagulation therapy in Subjects With Acute Submassive Pulmonary EmbolismDS-1040b is an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor (TAFIa) intended to be used for the treatment of thrombotic diseases including Pulmonary Embolism (PE)MedDRA version: 20.0 Level: HLT Classification code 10037379 Term: Pulmonary embolism and thrombosis System Organ Class: 100000004866MedDRA version: 20.0 Level: PT Classification code 10037377 Term: Pulmonary embolism System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
EUCTR2015-005211-32-NLDaiichi Sankyo, Inc.116
已完成
不适用
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Single Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of DS-1040b when Added to Standard of Care Anticoagulation Therapy in Subjects with Acute<br>Submassive Pulmonary Embolism.10014523Pulmonary embolism
NL-OMON47535Daiichi Sankyo, Inc22
尚未招募
1 期
A Study in Healthy Males and Females to Test How Different Doses of OPC-224333 are Tolerated (Arm 1)Neurological - EpilepsyEpilepsy
ACTRN12622000460707Otsuka Pharmaceutical Development & Commercialization, Inc72
已完成
1 期
A Trial in Healthy Participants to Evaluate the Pharmacokinetics, Safety, Tolerability and Food Effects of PRAX-562Epilepsy
ACTRN12620001292965Praxis Precision Medicines112